Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Here are over 20 gadgets that’ll help you achieve your New Year’s resolutions

January 11, 2026

Google pulls AI overviews for some medical searches

January 11, 2026

Death toll in crackdown on protests in Iran spikes to at least 538, activists say

January 11, 2026

I went looking for weird phones and CES 2026 did not disappoint

January 11, 2026

Snow, high winds, and freezing rain in the forecast for Atlantic Canada

January 11, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Thrombosis And Hemostasis Biomarkers Research Report 2023: Point-of-Care Analyzers Gain Traction – Global Forecast to 2030
Press Release

Thrombosis And Hemostasis Biomarkers Research Report 2023: Point-of-Care Analyzers Gain Traction – Global Forecast to 2030

By News RoomNovember 22, 20235 Mins Read
Thrombosis And Hemostasis Biomarkers Research Report 2023: Point-of-Care Analyzers Gain Traction – Global Forecast to 2030
Share
Facebook Twitter LinkedIn Pinterest Email
Thrombosis And Hemostasis Biomarkers Research Report 2023: Point-of-Care Analyzers Gain Traction – Global Forecast to 2030

Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) — The “Thrombosis And Hemostasis Biomarkers Market Size, Share & Trends Analysis Report By Product (Analyzers, Reagents & Consumables), By Test Location, By Test Type, By Application, By End-use, By Region, And Segment Forecasts, 2023-2030” report has been added to ResearchAndMarkets.com’s offering.

The global thrombosis and hemostasis biomarkers market size is expected to reach USD 7.92 Billion by 2030, expanding at a CAGR of 5.90% from 2023 to 2030

The rapid growth of the market is attributable to factors such as the increasing prevalence of chronic diseases such as pancreatic cancer, the rise in the geriatric population, the growing demand for personalized medicines, and advancements in technology.

The thrombosis & hemostasis biomarkers industry has grown significantly in recent years, with changes in adoption patterns and the introduction of novel technologies. The increasing trend of adopting POC analyzers in the market is creating traction for small-sized analyzers. Increasing research on mini- and microdevices is anticipated to continue over the coming years. For instance, in June 2022, Dr. Arnold Lining Ju announced the development of a microdevice that can detect blood clots and can be used to detect early signs of a heart attack.

The prevalence of chronic diseases such as deep vein thrombosis (DVT), pulmonary embolism (PE), and pancreatic cancer is anticipated drive the need for thrombosis & hemostasis biomarkers to detect the probability of hemostasis. Chronic diseases have a tendency to damage blood vessels, leading to the formation of clots that can block blood flow and cause serious health complications, such as stroke & heart attack. For instance, pulmonary embolism (PE), is a serious medical condition that occurs in the legs and travels to the lung, obstructing blood flow.

As per American Lung Association, in January 2023, PE affected nearly 900,000 people in the U.S. and nearly 33% of the people affected by (DVT) or pulmonary embolism (PE) experience recurrence of PE in ten years. Therefore, high prevalence and significant repetition of cases will lead to an increase in the demand for thrombosis & hemostasis biomarkers.

Furthermore, key players operating in the market are focusing on different forms of strategic initiatives such as mergers and acquisitions to increase their respective position in the thrombosis & hemostasis biomarkers industry. For instance, in January 2023, Thermo Fisher Scientific, Inc., announced a partnership with AstraZeneca to manufacture a blood-based and solid tissue companion diagnostic test for Tagrisso.

This was expected to propel the thrombosis and hemostasis biomarkers industry. Additionally, in May 2022, Quidel Corporation acquired Ortho Clinical Diagnostics for USD 6 billion. The new company was named QuidelOrtho. Through this acquisition, Quidel gained access to Ortho Clinical Diagnostics’ biomarker tests portfolio.

Thrombosis And Hemostasis Biomarkers Market Report Highlights

  • Reagents and consumables segment of the market held the largest revenue share in 2022 and is attributable to the heightened prevalence of bleeding and coagulation disorders in the global population
  • Clinical laboratory tests led the overall market in 2022, owing to their ability to diagnose and identify abnormalities in the blood clotting process while processing a high volume of samples
  • Post-thrombin (PT) test held the largest revenue share in 2022, attributable to the test quality which allows monitoring the effectiveness of anticoagulant medications
  • Deep Vein Thrombosis (DVT) held the largest revenue share in 2022, owing to its high prevalence and the high mortality risk
  • Diagnostic centers held the largest revenue share in 2022, attributable to the growing reliance of hospitals on diagnostic centers for testing and the presence of specialized equipment to provide faster test results
  • North America dominated the market in 2022 which can be attributed to a significant prevalence of thrombosis and hemostasis disorders, along with access to advanced technology

Key Attributes:

Report Attribute Details
No. of Pages 180
Forecast Period 2022 – 2030
Estimated Market Value (USD) in 2022 $5.01 Billion
Forecasted Market Value (USD) by 2030 $7.92 Billion
Compound Annual Growth Rate 5.9%
Regions Covered Global

Market Dynamics

Market Driver Analysis

  • Increasing Prevalence Of Chronic Diseases
  • Incidence Data Of Pancreatic Cancer
  • Growing Geriatric Population
  • Increasing Demand For Personalized Medicine
  • Advancements In Technology

Market Restraint Analysis

  • High Cost Of Diagnostic Tests
  • Complexity Of Thrombotic Events

Thrombosis & Hemostasis Biomarkers Market Analysis Tools

  • Porter’s Five Forces Analysis
  • Pestle Analysis

Competitive Landscape

  • Company Categorization
  • Strategy Mapping
  • New Product Launch
  • Partnerships
  • Acquisition
  • Collaboration
  • Funding
  • Key Company Market Share Analysis, 2022

Company Profiles

  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers
  • Abbott
  • BioMerieux SA
  • Werfen
  • HORIBA Ltd.
  • Quidel Corporation
  • Diazyme Laboratories, Inc.
  • Biomedica Diagnostics

Segment Analysis, By Product, 2018 – 2030 (USD Million)

  • Analyzers
  • Reagents & Consumables

Segment Analysis, By Test Location, 2018 – 2030 (USD Million)

  • Clinical Laboratory Tests
  • Point-Of-Care Tests

Segment Analysis, By Test Type, 2018 – 2030 (USD Million)

  • D-Dimer
  • Anti-Thrombin Iii
  • Plasminogen
  • Fibrin/Fibrinogen
  • Soluble Fibrin
  • Selectins
  • Factor Viii
  • Pt
  • Aptt
  • Others

Segment Analysis, By Application, 2018 – 2030 (USD Million)

  • Deep Vein Thrombosis (Dvt)
  • Pulmonary Embolism (Pe)
  • Disseminated Intravascular Coagulation (Dic)
  • Others

Segment Analysis, By End Use, 2018 – 2030 (USD Million)

  • Hospitals & Clinics
  • Academic & Research Institute
  • Diagnostic Centers
  • Others

For more information about this report visit https://www.researchandmarkets.com/r/cq1hlv

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Global Thrombosis and Hemostasis Biomarkers Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Supportive Living Services Expert Melissa Fields Shares Why Community Can Be Just as Important as Care for HelloNation

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardent Health

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

DeFi Crypto Mutuum Finance (MUTM) Reaches Over 18,700 Investors as V1 Protocol Launch Nears

Mutuum Finance (MUTM) Reports Ongoing Roadmap Progress With Halborn Security Audit Finalized

New Crypto Mutuum Finance (MUTM) Reports Development Progress with Over $19.7M Raised Since 2025

Stella Adler Foundation Reading of ‘All The President’s Men’ Sells Out With Cast Including: Mark Ruffalo, Ethan Hawke, Amy Brenneman, Don Cheadle, Kaley Cuoco, Laurence Fishburne, Spencer Garrett, Rob Morrow, Tom Pelphrey, Susan Traylor, Missy Yager, and More

Stella Adler Foundation Reading of ‘All The President’s Men’ Sells Out With Cast Including: Mark Ruffalo, Ethan Hawke, Amy Brenneman, Don Cheadle, Kaley Cuoco, Laurence Fishburn, Spencer Garrett, Rob Morrow, Tom Pelphrey, Susan Traylor, Missy Yager, and More

Property Value Explained by Real Estate Expert Luke Williams of Bowling Green, KY for HelloNation

Editors Picks

Google pulls AI overviews for some medical searches

January 11, 2026

Death toll in crackdown on protests in Iran spikes to at least 538, activists say

January 11, 2026

I went looking for weird phones and CES 2026 did not disappoint

January 11, 2026

Snow, high winds, and freezing rain in the forecast for Atlantic Canada

January 11, 2026

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

Instagram says it fixed the issue that sent password reset emails

January 11, 2026

Canadian government mulls response to X’s AI-generated sexual abuse material

January 11, 2026

Wing’s drone delivery is coming to 150 more Walmarts

January 11, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version